Discussion

The search for more predictive models of compound immunotoxicity has driven interest in the screening of primary cell models. While it is well appreciated that screening data from primary cells such as peripheral blood mononuclear cells (PBMCs) are more indicative of true compound or drug toxicity, the use of PBMCs in a screening assay context presents a unique set of challenges. Primarily, the limited availability and high costs of cells can be prohibitive to their usage in screening campaigns. Further, suspension cells pose challenges for traditional screening methods such as imaging.

IntelliCyt’s iQue® Screener is a high content, high throughput flow system that allows for multiplexability of assay readouts.The patented sampling technology is ideal for the screening of suspension cells, and in addition to significant miniaturization of assay volumes enables the rapid and cost effective screening of PBMCs.

For a high res .pdf please email mrackliff@intellicyt.com